Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Neutropenia is very common in patients received hematopoietic stem cell transplantation, with
median duration of about 14 days. In 2010 update, IDSA recommended Piperacillin/tazobactam as
first-line mono-therapy for febrile patients with neutropenia of high risk. In china, the
data of piperacillin/tazobactam for febrile neutropenia after hematopoietic stem cell
transplantation is very limited.
The current study will evaluate the efficacy of piperacillin/tazobactam compared with
imipenem/cilastatin for febrile neutropenia after transplantation.
Phase:
N/A
Details
Lead Sponsor:
Chinese PLA General Hospital
Treatments:
Imipenem Penicillanic Acid Piperacillin Piperacillin, Tazobactam Drug Combination Tazobactam